[{"id":"1ee70366-b7a8-4f46-abc0-90483806c589","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744652","created_at":"2021-01-18T07:38:47.984Z","updated_at":"2024-07-02T16:35:46.306Z","phase":"Phase 1","brief_title":"Dasatinib and Crizotinib in Advanced Cancer","source_id_and_acronym":"NCT01744652","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • ALK • MET • CDKN2A • DDR2 • CTGF","pipe":" | ","alterations":" BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification","tags":["BRAF • ALK • MET • CDKN2A • DDR2 • CTGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2023-06-07"},{"id":"a20d813c-0be4-46f6-9eac-b9a7b8cfecb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05187767","created_at":"2022-01-12T15:53:45.698Z","updated_at":"2024-07-02T16:36:00.723Z","phase":"","brief_title":"Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs","source_id_and_acronym":"NCT05187767","lead_sponsor":"University of Roma La Sapienza","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-11-08"},{"id":"0ef506df-7309-4725-94bc-cbf164085e5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439305","created_at":"2021-01-18T21:22:12.548Z","updated_at":"2024-07-02T16:36:43.039Z","phase":"Phase 2","brief_title":"Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)","source_id_and_acronym":"NCT04439305","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" DDR2","pipe":" | ","alterations":" DDR2 S768R","tags":["DDR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR2 S768R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 06/07/2018","primary_completion_date":" 06/07/2018","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-20"},{"id":"69112ba3-2ae8-4897-864e-b49a99d79bf1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03771404","created_at":"2021-01-18T18:39:31.761Z","updated_at":"2024-07-02T16:37:04.768Z","phase":"","brief_title":"NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized \"Liquid Biopsy\"","source_id_and_acronym":"NCT03771404","lead_sponsor":"Hellenic Oncology Research Group","biomarkers":" EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-12-11"}]